Blocking a key protein could reverse chemotherapy resistance in ovarian tumors

A team of scientists has uncovered the mechanism by which ovarian cancer cells evade the effects of platinum‑based chemotherapy and identified a molecular target that, when inhibited, re‑sensitises tumors to the treatment.

The study, published in Cell Reports, focused on cisplatin—a cornerstone drug for ovarian and several other cancers. While its DNA‑damaging action is well known, the researchers demonstrated that the drug also interferes with the cell’s microtubule network, the structural framework that supports cell integrity.

“We discovered that malignant cells remodel their internal architecture to survive chemotherapy,” explains Sachi Horibata, assistant professor in the Precision Health Program and the pharmacology and toxicology department at Michigan State University College of Human Medicine. “These adaptations enable them to persist despite drug exposure.”

Conversely, patients whose tumors exhibited low TPPP3 expression experienced longer survival and better therapeutic outcomes. Experimental knock‑down of TPPP3 in cell cultures restored susceptibility to cisplatin, highlighting a potential strategy to overcome drug resistance.

“TPPP3 functions as a defensive barrier for cancer cells,” Horibata notes. “Eliminating this shield weakens the tumor’s protection and allows the chemotherapy to act more efficiently.”

The findings also shed light on the clinical phenomenon of relapse after an initial period of remission. Inspired by her grandmother’s battle with ovarian cancer, Horibata sought to decipher why some tumours initially respond then recur with heightened aggressiveness.

Rather than focusing solely on DNA repair, the team showed that cancer cells can reprogram the “tubulin code”—a series of modifications that stabilise microtubules under stress—thereby sustaining survival pathways.

By shifting attention from genetic damage to the physical scaffolding of malignant cells, the research opens avenues for enhancing existing chemotherapy regimens instead of discarding them.

Future work will aim to develop TPPP3‑directed inhibitors and evaluate the protein’s utility as a predictive biomarker for resistance. Additional studies will explore how this mechanism interacts with combination therapies and whether it plays a role in other cancer types.

“Understanding the ways tumours adapt to treatment is essential for staying ahead of the disease,” Horibata says. “Targeting those adaptive processes could make current drugs more potent, durable, and tailored to individual patients.”

The broader impact of this discovery may extend to mitigating common side effects of platinum agents—such as neuropathy, alopecia and ototoxicity—since microtubules are also critical in normal tissues.